Sorafenib (Nexavar, sorafenib tosylate, BAY 43-9006)
Brand Name: Nexavar
Generic Name: sorafenib tosylate
Code Name: BAY 43-9006
Company: Bayer
FDA Clinical Phase: 1, 2
Description:
Sorafenib is a kinase inhibitor that stops cells from dividing and may also prevent the growth of new blood vessels that tumors need for growth (known as angiogenesis). Sorafenib is a drug used to treat advanced kidney cancer and a type of liver cancer. It is also being studied for treating other cancers.
Clinical Trials:
Currently, there are two clinical trials with sorafenib recruiting patients. One study is using a combination of Sorafenib and Everolimus. Another study is a Phase 1 trial using Sorafenib in combination with Velcade (bortezomib). Both clinical trials are recruiting adults and senior patients of both genders.
Source: http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=390251
Related Articles:
- Perifosine Advances To Phase 3 Multiple Myeloma Clinical Trial
- Nexavar Shows No Effect In Phase 2 Study (ASCO 2009)
- New Clinical Trials Combine Zolinza And Velcade For Multiple Myeloma Treatment
- Phase 3 Zolinza-Velcade Trial Opening Soon
- IMW 2009 – Elotuzumab And Panobinostat Clinical Trials With Velcade
Leave a comment